دورية أكاديمية
The osteogenic and angiogenic potential of microRNA-26a delivered via a non-viral delivery peptide for bone repair.
| العنوان: | The osteogenic and angiogenic potential of microRNA-26a delivered via a non-viral delivery peptide for bone repair. |
|---|---|
| المؤلفون: | Chambers P; School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK., Ziminska M; School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK., Elkashif A; School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK., Wilson J; School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK., Redmond J; School of Mechanical and Manufacturing Engineering, Dublin City University, Dublin 9, Ireland., Tzagiollari A; School of Mechanical and Manufacturing Engineering, Dublin City University, Dublin 9, Ireland., Ferreira C; Department of Biomedical Engineering, University of Massachusetts, Amherst, United States., Balouch A; Department of Biomedical Engineering, University of Massachusetts, Amherst, United States., Bogle J; Department of Biomedical Engineering, University of Massachusetts, Amherst, United States., Donahue SW; Department of Biomedical Engineering, University of Massachusetts, Amherst, United States., Dunne NJ; School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK; School of Mechanical and Manufacturing Engineering, Dublin City University, Dublin 9, Ireland; Biodesign Europe, Dublin City University, Dublin 9, Ireland; Centre for Medical Engineering Research, School of Mechanical and Manufacturing Engineering, Dublin City University, Dublin 9, Ireland; Department of Mechanical and Manufacturing Engineering, School of Engineering, Trinity College Dublin, Dublin 2, Ireland; Advanced Manufacturing Research Centre (I-Form), School of Mechanical and Manufacturing Engineering, Dublin City University, Glasnevin, Dublin 9, Ireland; Advanced Materials and Bioengineering Research Centre (AMBER), Royal College of Surgeons in Ireland and Trinity College Dublin, Dublin, Ireland; Advanced Processing Technology Research Centre, Dublin City University, Dublin 9, Ireland; Trinity Centre for Biomedical Engineering, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland., McCarthy HO; School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK. Electronic address: h.mccarthy@qub.ac.uk. |
| المصدر: | Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2023 Oct; Vol. 362, pp. 489-501. Date of Electronic Publication: 2023 Sep 09. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam : Elsevier Science Publishers, 1984- |
| مستخلص: | Bone-related injuries and diseases are among the most common causes of morbidity worldwide. Current bone-regenerative strategies such as auto- and allografts are invasive by nature, with adverse effects such as pain, infection and donor site morbidity. MicroRNA (miRNA) gene therapy has emerged as a promising area of research, with miRNAs capable of regulating multiple gene pathways simultaneously through the repression of post-transcriptional mRNAs. miR-26a is a key regulator of osteogenesis and has been found to be upregulated following bone injury, where it induces osteodifferentiation of mesenchymal stem cells (MSCs) and facilitates bone formation. This study demonstrates, for the first time, that the amphipathic, cell-penetrating peptide RALA can efficiently deliver miR-26a to MSCs in vitro to regulate osteogenic signalling. Transfection with miR-26a significantly increased expression of osteogenic and angiogenic markers at both gene and protein level. Using a rat calvarial defect model with a critical size defect, RALA/miR-26a NPs were delivered via an injectable, thermo-responsive Cs-g-PNIPAAm hydrogel to assess the impact on both rate and quality of bone healing. Critical defects treated with the RALA/miR-26a nanoparticles (NPs) had significantly increased bone volume and bone mineral density at 8 weeks, with increased blood vessel formation and mechanical properties. This study highlights the utility of RALA to deliver miR-26a for the purpose of bone healing within an injectable biomaterial, warranting further investigation of dose-related efficacy of the therapeutic across a range of in vivo models. (Copyright © 2023. Published by Elsevier B.V.) |
| فهرسة مساهمة: | Keywords: Bone; Calvarial defect; DNA; Nanoparticle; Osteogenesis; RALA peptide; miR26a; microRNA |
| تواريخ الأحداث: | Date Created: 20230906 Latest Revision: 20231012 |
| رمز التحديث: | 20231013 |
| DOI: | 10.1016/j.jconrel.2023.09.006 |
| PMID: | 37673308 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1873-4995 |
|---|---|
| DOI: | 10.1016/j.jconrel.2023.09.006 |